Anavex Life Sciences Corp (AVXL)

[WolfWayne]

I've wondered the same.

"This poster reports positive cognitive EEG/ERP P300 data of the first initial 12 out of 32 mild-to-moderate Alzheimer’s patients (MMSE 16-28) mostly on donepezil, the current standard of care at end of Part A (day 36)."

"ANAVEX2-73 improves the P300 signal in 10 out of 12 (83%) patients".

What was different about the other 2? Were 10 of 12 patients already taking donepezil? Were 2 of 12 taking only 2-73? Does the lack of dose optimization suggest 2-73 has yet to be effectively dosed in patients not taking donepezil?

Too early to tell it seems but still a concern, right?